Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates
09:15am, Monday, 04'th Aug 2025
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.06 per share a year ago.
BioCryst (BCRX) Q2 Revenue Jumps 50%
07:24am, Monday, 04'th Aug 2025
BioCryst (BCRX) Q2 Revenue Jumps 50%
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update
07:00am, Monday, 04'th Aug 2025
—Q2 2025 ORLADEYO net revenue of $156.8 million (+45 percent y-o-y)— —Q2 2025 operating profit of $29.8 million (+239 percent y-o-y); non-GAAP operating profit of $57.0 million (+160 percent y-o
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
02:16pm, Thursday, 31'st Jul 2025
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
07:00am, Thursday, 31'st Jul 2025
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has infor
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Monday, 28'th Jul 2025
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst to Report Second Quarter 2025 Financial Results on August 4
07:00am, Monday, 21'st Jul 2025
RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2025 financial results on
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit
07:00am, Wednesday, 09'th Jul 2025
RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?
10:41am, Monday, 07'th Jul 2025
Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
07:00am, Monday, 07'th Jul 2025
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head o
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 03'rd Jul 2025
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted e
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
07:00am, Friday, 27'th Jun 2025
—Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to
BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 25'th Jun 2025
BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
5 Must-Buy Efficient Stocks to Buy for Solid Gains Amid Volatility
08:55am, Wednesday, 25'th Jun 2025
INSW, ASR, BCRX, ASC and RRGB top the list of highly efficient stocks poised for gains amid market volatility.
New Strong Buy Stocks for June 25th
07:21am, Wednesday, 25'th Jun 2025
BILI, AEM, EVR, VEEV and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on June 25, 2025.
